LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2016-10-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of 84 successive days of topically
administered LHA510 compared to vehicle in reducing the number of patients requiring
intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for
recurrence of active choroidal neovascularization (CNV).